Clinical Trials And Product DevelopmentPrecision's PBGENE-HBV represents a novel treatment approach with the potential to achieve the clinical goals of a functional cure for CHB, poised to be the first and only potentially curative gene editing program to enter the clinic.
Financial Health And MilestonesPrecision ended the year with a strong cash position, providing a financial runway into the latter half of the decade, ensuring the company is well-equipped to hit multiple milestones in validating their ARCUS genome editing technology.
Innovation And Market PositionWith in vivo data showing up to 45% high-efficiency gene insertion in non-dividing cells of non-human primates, Precision BioSciences is carving out a leading position in the gene editing space, leveraging their ARCUS technology.